What we look for
We are looking to partner with ambitious, rapidly growing firms where we can add value through relevant, specialist knowledge and connections. If there is a technological aspect to your business, we will be pleased to hear from you, and if it does not quite fit what we are looking for, we will let you know.
Specific areas of focus and expertise are explained below. We have also produced a PDF version of this guide which you can request by e-mailing email@example.com.
Healthcare Technologies such as medical devices; diagnostics; drug delivery; specialty pharma; life science research tools and other enabling technologies. In general we do not fund small molecule drug discovery, but we look at every opportunity on a case-by-case basis and do not rule it out.
Information and Communications Technologies including mobile and other telecommunications technologies, consumer internet, new media, enterprise software, business services solutions and enabling technologies for these areas.
Sustainability and adjacent technologies such as materials science; advanced engineering (e.g. metrology); water and air technologies; waste management; clean energy; energy efficiency, agricultural technologies. Many businesses involved in “sustainability” or “cleantech” bring together several distinct areas of technology and we see it as one of our core strengths that we are able to analyse and add value to opportunities building on the convergence of diverse scientific fields.
We will take part in rounds of between £0.5 million and £10 million.
We see it as an advantage to partner with other institutional investors. This brings many benefits beyond simply putting more cash on the table, as it enables an investee company to benefit from more experience across diverse fields.
We expect to join a company’s Board of Directors where we feel we have something to add. It is unlikely that we will invest in a company where we feel we cannot add value. In all cases we expect the highest standards of investor reporting and corporate governance.
- Oxitec report 96% suppression of the dengue mosquito in Brazilian trials
- Celoxica launches new product range and raises additional capital